prostate cancer

FDA
Favicon Fierce Biotech

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

The FDA has taken issue with camizestrant's trial design and questions the Truqap data's clinical meaningfulness.
Angus Liu Apr 28, 2026 2:47pm
Narasimhan

Novartis stands by $5B Pluvicto goal despite EU regulatory setback

Apr 28, 2026 10:10am
Lawsuit over pharma drugs

Bayer falls short in bid to block J&J’s survival claims

Apr 20, 2026 8:24am
NVS

Novartis pumps up heart disease, cancer community health plan

Apr 10, 2026 4:43am
On target clinical trial success bullseye score

Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win

Mar 19, 2026 6:45am
FDA conference hall
Favicon Fierce Biotech

FDA to end 9-month adcomm hiatus with review of AZ cancer drugs

Mar 6, 2026 11:16am